JP2015502551A - Ａβ凝集体の選択的定量化方法 - Google Patents

Ａβ凝集体の選択的定量化方法 Download PDF

Info

Publication number
JP2015502551A
JP2015502551A JP2014548051A JP2014548051A JP2015502551A JP 2015502551 A JP2015502551 A JP 2015502551A JP 2014548051 A JP2014548051 A JP 2014548051A JP 2014548051 A JP2014548051 A JP 2014548051A JP 2015502551 A JP2015502551 A JP 2015502551A
Authority
JP
Japan
Prior art keywords
aggregates
aggregate
substrate
probe
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014548051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502551A5 (enExample
Inventor
ヴィルボルト ディーター
ヴィルボルト ディーター
フンケ スーザンアイリーン
アイリーン フンケ スーザン
レ
ワン−ディートリヒ レイ
ビアクマン エーファ
バナッハ オリヴァー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungszentrum Juelich GmbH
Original Assignee
Forschungszentrum Juelich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forschungszentrum Juelich GmbH filed Critical Forschungszentrum Juelich GmbH
Publication of JP2015502551A publication Critical patent/JP2015502551A/ja
Publication of JP2015502551A5 publication Critical patent/JP2015502551A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/552—Glass or silica
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
JP2014548051A 2011-12-23 2012-12-21 Ａβ凝集体の選択的定量化方法 Pending JP2015502551A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011057021.7 2011-12-23
DE102011057021A DE102011057021A1 (de) 2011-12-23 2011-12-23 Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten
PCT/EP2012/076552 WO2013092952A2 (de) 2011-12-23 2012-12-21 Verfahren zur selektiven quantifizierung von a-beta-aggregaten

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018189249A Division JP6625709B2 (ja) 2011-12-23 2018-10-04 Ａβ凝集体の選択的定量化方法

Publications (2)

Publication Number Publication Date
JP2015502551A true JP2015502551A (ja) 2015-01-22
JP2015502551A5 JP2015502551A5 (enExample) 2017-03-02

Family

ID=47624003

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014548051A Pending JP2015502551A (ja) 2011-12-23 2012-12-21 Ａβ凝集体の選択的定量化方法
JP2018189249A Expired - Fee Related JP6625709B2 (ja) 2011-12-23 2018-10-04 Ａβ凝集体の選択的定量化方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018189249A Expired - Fee Related JP6625709B2 (ja) 2011-12-23 2018-10-04 Ａβ凝集体の選択的定量化方法

Country Status (12)

Country Link
US (1) US20150024512A1 (enExample)
EP (1) EP2794655B1 (enExample)
JP (2) JP2015502551A (enExample)
CN (1) CN104080807A (enExample)
BR (1) BR112014015392A2 (enExample)
CA (1) CA2858125A1 (enExample)
DE (1) DE102011057021A1 (enExample)
DK (1) DK2794655T3 (enExample)
ES (1) ES2922201T3 (enExample)
IL (1) IL232870B (enExample)
RU (1) RU2642314C2 (enExample)
WO (1) WO2013092952A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017138497A1 (ja) * 2016-02-08 2017-08-17 シスメックス株式会社 被検物質の検出方法および被検物質の検出用試薬キット
JP2020523554A (ja) * 2017-06-13 2020-08-06 フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 試料中におけるバイオ治療物質凝集体の検出方法
JP2021504675A (ja) * 2017-11-23 2021-02-15 フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 試料中のタンパク質ミスフォールディング疾患のタンパク質凝集体を定量化する方法
JP2021508370A (ja) * 2017-12-19 2021-03-04 チェイス セラピューティクス コーポレイション 神経変性状態を処置するための医薬を開発するための方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013106713A1 (de) * 2013-06-26 2014-12-31 Forschungszentrum Jülich GmbH Verfahren zur Ermittlung von Indikatoren zur Bestimmung von Krankheiten
WO2016053621A1 (en) * 2014-09-16 2016-04-07 Sri International Affinity reagent and catalyst discovery though fiber-optic array scanning technology
DE102015003404B4 (de) * 2015-03-18 2021-10-07 Forschungszentrum Jülich GmbH Verfahren zur Herstellung eines Standards für den Nachweis von Proteinaggregaten einer Proteinfehlfaltungserkrankung sowie Standard und dessen Verwendung
JP6886854B2 (ja) * 2017-04-13 2021-06-16 シスメックス株式会社 被検物質の情報取得方法
DE102017005543A1 (de) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Verfahren zum Nachweis von Extrazellulären Vesikeln in einer Probe
CN111518206B (zh) 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
DE102020114278A1 (de) 2020-05-28 2021-12-02 Forschungszentrum Jülich GmbH Bestimmung krankheitsspezifischer Protein-Aggregate in Stuhlproben
DE102020003794A1 (de) * 2020-06-25 2021-12-30 Forschungszentrum Jülich GmbH Verfahren, Verwendung des Verfahrens sowle Kit zum Nachweis von Bioindikatoren in einer Probe
CN116879540B (zh) * 2023-07-13 2024-04-05 香港中文大学（深圳） 一种神经元蛋白聚集体特异性检测试剂盒

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04501605A (ja) * 1988-11-10 1992-03-19 フアーマシア・ビオセンソル・アクチエボラーグ バイオセンサーシステムに使用する選択的生体分子相互作用の可能な検出表面
JP2008510167A (ja) * 2004-08-19 2008-04-03 バイオセプト インコーポレイテッド マイクロアレイ分析における非特異的結合の軽減
WO2009051220A1 (ja) * 2007-10-19 2009-04-23 Immunas Pharma, Inc. Aβオリゴマーに特異的に結合する抗体およびその利用
WO2009136499A1 (ja) * 2008-05-08 2009-11-12 武田薬品工業株式会社 Ａβオリゴマー測定法
WO2010074083A1 (ja) * 2008-12-24 2010-07-01 コニカミノルタホールディングス株式会社 表面プラズモンおよび蛍光共鳴エネルギー転移を利用した免疫アッセイ
WO2011100292A1 (en) * 2010-02-09 2011-08-18 Bristol-Myers Squibb Company Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
SG10201706600VA (en) * 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
CN101384279B (zh) * 2006-02-24 2012-02-22 奇斯药制品公司 抗淀粉样蛋白免疫原性组合物、方法和用途
WO2008070229A2 (en) * 2006-08-28 2008-06-12 Case Western Reserve University Detection of pathogenic aggregates of protein in a sample by homologous elisa
US8512677B2 (en) * 2009-04-27 2013-08-20 Case Western Reserve University Pyro-glutamate Aβ targeting agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04501605A (ja) * 1988-11-10 1992-03-19 フアーマシア・ビオセンソル・アクチエボラーグ バイオセンサーシステムに使用する選択的生体分子相互作用の可能な検出表面
JP2008510167A (ja) * 2004-08-19 2008-04-03 バイオセプト インコーポレイテッド マイクロアレイ分析における非特異的結合の軽減
WO2009051220A1 (ja) * 2007-10-19 2009-04-23 Immunas Pharma, Inc. Aβオリゴマーに特異的に結合する抗体およびその利用
WO2009136499A1 (ja) * 2008-05-08 2009-11-12 武田薬品工業株式会社 Ａβオリゴマー測定法
WO2010074083A1 (ja) * 2008-12-24 2010-07-01 コニカミノルタホールディングス株式会社 表面プラズモンおよび蛍光共鳴エネルギー転移を利用した免疫アッセイ
WO2011100292A1 (en) * 2010-02-09 2011-08-18 Bristol-Myers Squibb Company Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SUSANNE AILEEN FUNKE: "SINGLE PARTICLE DETECTION OF Aβ AGGREGATES WITH ALZHEIMER'S DISEASE", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. V364 N4, JPN5015002338, 24 October 2007 (2007-10-24), US, pages 902 - 907, ISSN: 0003804929 *
SUSANNE AILEEN FUNKE: "SINGLE-PARTICLE DETECTION SYSTEM FOR Aβ AGGREGATES:ADAPTATION OF SURFACE-FLUORESCENCE INTENSITY DIS", REJUVENATION RESEARCH, vol. V13 N2-3, JPN5015002340, 4 December 2009 (2009-12-04), pages 206 - 209, ISSN: 0003804930 *
WANG-DIETRICH LEI, JOURNAL OF ALZHEIMERS DISEASE, vol. V34 N4, JPN5015002341, 1 January 2013 (2013-01-01), pages 985 - 994, ISSN: 0003583863 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017138497A1 (ja) * 2016-02-08 2017-08-17 シスメックス株式会社 被検物質の検出方法および被検物質の検出用試薬キット
JP2020523554A (ja) * 2017-06-13 2020-08-06 フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 試料中におけるバイオ治療物質凝集体の検出方法
JP2021504675A (ja) * 2017-11-23 2021-02-15 フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 試料中のタンパク質ミスフォールディング疾患のタンパク質凝集体を定量化する方法
JP2021508370A (ja) * 2017-12-19 2021-03-04 チェイス セラピューティクス コーポレイション 神経変性状態を処置するための医薬を開発するための方法
JP7495878B2 (ja) 2017-12-19 2024-06-05 チェイス セラピューティクス コーポレイション 神経変性状態を処置するための医薬を開発するための方法

Also Published As

Publication number Publication date
ES2922201T3 (es) 2022-09-09
EP2794655A2 (de) 2014-10-29
JP6625709B2 (ja) 2019-12-25
CN104080807A (zh) 2014-10-01
DK2794655T3 (da) 2022-07-18
RU2014130136A (ru) 2016-02-10
EP2794655B1 (de) 2022-04-13
RU2642314C2 (ru) 2018-01-24
BR112014015392A2 (pt) 2019-09-24
IL232870A0 (en) 2014-07-31
CA2858125A1 (en) 2013-06-27
IL232870B (en) 2020-06-30
DE102011057021A1 (de) 2013-06-27
WO2013092952A2 (de) 2013-06-27
US20150024512A1 (en) 2015-01-22
WO2013092952A3 (de) 2013-08-29
JP2019015738A (ja) 2019-01-31

Similar Documents

Publication Publication Date Title
JP6625709B2 (ja) Ａβ凝集体の選択的定量化方法
JP6478987B2 (ja) 表面ｆｉｄａの使用下でのタンパク質凝集体の測定方法
CA2395789C (en) Methods of detection of amyloidogenic proteins
JP2015502551A5 (enExample)
JP2011514963A (ja) 細胞応答のデュアル検出システム及び方法
JP2015502968A (ja) 生体固有のタンパク質からの病原性の凝集体を定量化するための標準物質
US20230228771A1 (en) Determination of disease-specific protein aggregates in stool samples
EP2480891B1 (en) Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
KR101492167B1 (ko) 페리틴 단백질을 함유하는 표적-특이적 프로브 및 이를 이용한 바이오마커의 탐지
BR102021022687A2 (pt) Método e reagentes para diagnosticar nefropatia membranosa
JP2020523554A (ja) 試料中におけるバイオ治療物質凝集体の検出方法
US20080003691A1 (en) Method of Detecting Conformational Change of an Amyloid Protein, a Method of Searching a Substance Having an Activity that Affects to Conformational Change of an Amyloid Protein, and Method of Searching a Therapeutic or Diagnostic Agent for Amyloid-Related Diseases
CA2656417C (en) Process for the selective determination of pathological protein deposits
Huhn et al. eSylites: Synthetic Probes for Visualization and Topographic Mapping of Single Excitatory Synapses
JP2021504675A (ja) 試料中のタンパク質ミスフォールディング疾患のタンパク質凝集体を定量化する方法
Emin Single-molecule studies of alpha-synuclein and abeta in Parkinson’s disease derived biofluids
Praseetha et al. Molecular Nanobiotechnological approaches for the detection and therapy of prion related diseases.
Hadavi et al. Section 1-Buffer 4-ethylmorpholine/acetate maintains solution-phase folding for native mass spectrometry of proteins and proteins complexes

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150918

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161222

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180604